WNT signaling modulates chemoresistance to temozolomide in p53-mutant glioblastoma multiforme

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme (GBM) exhibits high recurrence rates and resistance to chemotherapy, notably temozolomide (TMZ).
• The precise molecular mechanisms underlying TMZ resistance in GBM are not fully understood.
• O6-methylguanine DNA methyltransferase (MGMT) is a known factor in TMZ resistance, but its role in conjunction with other pathways is complex.

Purpose of the Study:

• To elucidate the molecular mechanisms of temozolomide (TMZ) resistance in glioblastoma (GBM).
• To investigate the role of WNT signaling in mediating drug response and chemoresistance in GBM.
• To identify potential therapeutic targets for overcoming TMZ resistance in p53-mutant GBM.

Main Methods:

• Analysis of WNT signaling pathway activation in response to TMZ treatment in GBM models.
• Investigation of the relationship between p53 mutation status, miR-34a expression, and WNT6 regulation.
• In vitro drug sensitivity assays and in vivo xenograft studies using combined TMZ treatment with WNT inhibitors or miR-34a mimics.

Main Results:

• TMZ treatment amplifies WNT signaling, contributing to chemoresistance in GBM.
• In p53-mutant GBM, loss of p53 function downregulates miR-34a, leading to WNT6 upregulation and WNT pathway activation.
• MGMT's role in chemoresistance was found to be redundant to WNT-mediated resistance in this context.
• Combined TMZ and WNT inhibition or miR-34a mimic treatment sensitized p53-mutant GBM cells to the drug and improved survival in mice.

Conclusions:

• WNT signaling activation, driven by miR-34a/WNT6 axis dysregulation in p53-mutant GBM, is a key mechanism of TMZ resistance.
• Targeting the miR-34a/WNT6 axis in combination with TMZ offers a promising therapeutic strategy for p53-mutant GBM.
• These findings provide novel insights for developing effective treatments against glioblastoma chemoresistance.